FTH1 (Ferritin Heavy Chain 1) is a fundamental iron-storage protein that plays a critical role in maintaining iron homeostasis in the brain. As part of the ferritin heteropolymer, FTH1 is essential for sequestering excess iron and preventing iron-mediated oxidative damage, a key contributor to neurodegenerative processes.
| FTH1 Protein |
|---|
| Gene | [FTH1](/genes/fth1) |
| UniProt ID | [P02794](https://www.uniprot.org/uniprotkb/P02794) |
| PDB Structures | 2FHA, 3AJO, 4ZJ7 |
| Molecular Weight | ~21 kDa (subunit) |
| Subcellular Localization | Cytosol, nucleus, mitochondria |
| Protein Family | Ferritin family |
FTH1 is a 21 kDa subunit that assembles with FTL (ferritin light chain) to form the 24-subunit ferritin nanocage. Each subunit contains:
- Ferroxidase center: Catalyzes Fe(II) oxidation to Fe(III) for iron storage
- Channel pores: Allow iron entry and release
- N-terminal domain: Involved in protein-protein interactions
The structure is highly conserved across species, with the ferroxidase activity residing primarily in the heavy chain subunits.
In the nervous system, FTH1 serves several essential functions:
- Iron Homeostasis: Sequesters excess intracellular iron in a soluble, non-toxic form
- Oxidative Stress Protection: Prevents Fenton chemistry that generates reactive oxygen species (ROS)
- Neuroprotection: Supports neuronal survival under oxidative stress conditions
- Myelin Maintenance: Essential for oligodendrocyte function and myelin synthesis
- Dendritic Iron Regulation: Modulates iron levels in dendritic processes
FTH1 is highly expressed in neurons, astrocytes, and oligodendrocytes, with particularly high levels in the substantia nigra and basal ganglia.
- Iron accumulation: Elevated iron levels in amyloid plaques and neurofibrillary tangles correlate with FTH1 upregulation
- Oxidative stress: Dysregulated iron homeostasis contributes to amyloid-beta toxicity
- Therapeutic implications: Ferritin levels in cerebrospinal fluid serve as a biomarker for AD progression
- Neuromelanin interaction: FTH1 interfaces with neuromelanin in the substantia nigra
- Iron dysregulation: Post-mortem studies show increased ferritin in PD brains
- Substantia nigra vulnerability: Region-specific iron accumulation parallels dopaminergic neuron loss
- Autosomal dominant disorder: Caused by FTH1 mutations affecting iron storage
- Basal ganglia degeneration: Leads to chorea, dystonia, and cognitive decline
- Ferroxidase dysfunction: Mutations impair iron oxidation and storage capacity
- Amyotrophic Lateral Sclerosis (ALS): Altered ferritin levels in motor neurons
- Friedreich's Ataxia: Interaction with frataxin deficiency affects iron metabolism
- Huntington's Disease: Dysregulated iron homeostasis contributes to pathology
Current therapeutic approaches targeting FTH1 and iron metabolism include:
| Agent |
Mechanism |
Status |
| Deferoxamine |
Iron chelation |
Clinical trials for AD/PD |
| Deferasirox |
Oral iron chelator |
Investigational for PD |
| Clioquinol |
Metal-protein attenuating compound |
Phase II for AD |
| M30 |
Iron chelator with neuroprotective activity |
Preclinical |
- Connor et al., Ferritin in the aging brain (1992)
- Quintana et al., Iron and Parkinson's disease (2006)
- Cozzi et al., Neuroferritinopathy mutations (2013)
- Wang et al., Ferritin in Alzheimer's disease (2021)
- Schmuck et al., Iron chelation therapy in neurodegeneration (2022)